Journal of Menopausal Medicine最新文献

{"title":"The Association between Sexual Self-Efficacy and the Quality of Life among Menopausal Women.","authors":"Tahereh Jalali,&nbsp;Zahra Bostani Khalesi,&nbsp;Fatemeh Jafarzadeh-Kenarsari","doi":"10.6118/jmm.21006","DOIUrl":"https://doi.org/10.6118/jmm.21006","url":null,"abstract":"<p><strong>Objectives: </strong>The present study aimed to determine the association between sexual self-efficacy (SSE) and quality of life (QOL) among menopausal women.</p><p><strong>Methods: </strong>In this analytical cross-sectional study, 558 menopausal women were enrolled. Consecutive and available sampling was performed for the sample collection. The instruments used for data collection included a three-part questionnaire consisting of demographic information, Menopausal-Specific Quality of Life Questionnaire (MENQOL), and SSE questionnaire.</p><p><strong>Results: </strong>Overall, the maximum and minimum scores of SSE were related to sexual desire (2.88 ± 0.60) and orgasm (0.85 ± 0.17). The highest and lowest scores of QOL were related to psychosocial (4.14 ± 1.24) and sexual activity (3.03 ± 1.74) domains. A significant correlation was observed between the QOL and the domains of SSE (<i>P</i> < 0.001). The maximum and minimum correlation of QOL were related to sexual desire (<i>P</i> < 0.001, r = 0.030) and orgasm (<i>P</i> < 0.001, r = 0.108), respectively. Furthermore, a significant correlation was observed between the SSE score and all domains of QOL except for the vasomotor domain. With regard to the SSE score, the maximum association was found with the sexual activity score (<i>P</i> < 0.001, r = 0.466).</p><p><strong>Conclusions: </strong>Based on the findings of this study, a significant direct correlation was observed between the QOL and SSE of menopausal women. Thus, further research and developing education and consultation as intervention programs for enhancing SSE can promote the QOL among women.</p>","PeriodicalId":16410,"journal":{"name":"Journal of Menopausal Medicine","volume":"27 2","pages":"87-93"},"PeriodicalIF":0.0,"publicationDate":"2021-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/db/9b/jmm-27-87.PMC8408323.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39371521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Spontaneous Rupture of Ovarian Artery Aneurysm in a Postmenopausal Woman: A Case Report and Literature Review.","authors":"Yoon Hyeon Hu,&nbsp;Yung-Taek Ouh,&nbsp;Chorong Kim,&nbsp;Se Jin Lee,&nbsp;Tae Gyu Ahn,&nbsp;Hyang Ah Lee","doi":"10.6118/jmm.21015","DOIUrl":"https://doi.org/10.6118/jmm.21015","url":null,"abstract":"<p><p>Spontaneous rupture of an ovarian artery aneurysm is an extremely rare, life-threatening disease and has been reported to be most highly associated with pregnancy. The current study presents a case of intraperitoneal and retroperitoneal hematoma caused by spontaneous rupture of a right ovarian artery aneurysm in a 56-year-old woman. A 56-year-old woman visited the emergency room with right lower quadrant abdominal pain. Contrast-enhanced computed tomography showed a large retroperitoneal and intraperitoneal hematoma and active extravasation of contrast medium in the right retroperitoneum. Consequently, transcatheter arterial embolization was successfully performed. Spontaneous rupture of an ovarian artery aneurysm should be suspected in multiparous women with abdominal or flank pain even if it is unrelated to pregnancy. Suspicion of this entity is needed for earlier diagnosis and management.</p>","PeriodicalId":16410,"journal":{"name":"Journal of Menopausal Medicine","volume":"27 2","pages":"102-105"},"PeriodicalIF":0.0,"publicationDate":"2021-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/8d/9b/jmm-27-102.PMC8408319.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39369435","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of Alkaline Drinking Water on Bone Density of Postmenopausal Women with Osteoporosis.","authors":"Sanaz Fasihi, Siavash Fazelian, Farinaz Farahbod, Fateme Moradi, Morteza Dehghan","doi":"10.6118/jmm.20036","DOIUrl":"10.6118/jmm.20036","url":null,"abstract":"<p><strong>Objectives: </strong>Postmenopausal women are predisposed to osteoporosis, and those on acidic diets are at a higher risk, because it has been demonstrated that such diets have adverse effects on bone health. In this study, the effect of alkaline drinking water on bone mineral density was evaluated in postmenopausal women with osteoporosis.</p><p><strong>Methods: </strong>One hundred postmenopausal women with osteoporosis (T-score ≤ -2.5) were equally divided into an intervention group and a control group (n = 50 each). The intervention group received calcium D (daily), alkaline drinking water (1.5 L daily with pH 8.6 ± 0.3), and Osteofos tablet (70 mg weekly), whereas the control group received only calcium D and Osteofos tablet for 3 months. T-scores of the femur and spine bones were obtained using bone densitometry before and 3 months after the intervention.</p><p><strong>Results: </strong>After the intervention, the mean T-scores of the femur and spine bones significantly increased in both the control and intervention groups (<i>P</i> < 0.05). However, the mean changes in the spine T-score were significantly higher in the intervention group (0.39 ± 0.07) than in the control group (0.08 ± 0.01) (<i>P</i> < 0.05). No significant differences were observed in the mean changes in the femur T-score between the two groups.</p><p><strong>Conclusion: </strong>Our findings demonstrate that drinking alkaline water improves spine T-scores in postmenopausal women with osteoporosis. Hence, alkaline water can be used to treat osteoporosis due to increased bone density in postmenopausal women. Long-term interventions are necessary to confirm the effects of alkaline water on femur density.</p>","PeriodicalId":16410,"journal":{"name":"Journal of Menopausal Medicine","volume":"27 2","pages":"94-101"},"PeriodicalIF":0.0,"publicationDate":"2021-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ee/06/jmm-27-94.PMC8408322.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39371522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Levonorgestrel-Releasing Intrauterine System Use in Perimenopausal Women.","authors":"Jong-Kil Joo,&nbsp;Jung-Ho Shin,&nbsp;Jung Ryeol Lee,&nbsp;Mee-Ran Kim","doi":"10.6118/jmm.20038","DOIUrl":"https://doi.org/10.6118/jmm.20038","url":null,"abstract":"<p><p>The levonorgestrel-releasing intrauterine system (LNG-IUS) is a highly effective contraceptive method that has several noncontraceptive benefits. It has been used in various gynecological conditions, such as heavy menstrual bleeding, dysmenorrhea, and endometrial hyperplasia. During the perimenopausal period, hormonal fluctuations occur, and there is a high tendency for the development of several benign gynecologic diseases. Therefore, the use of LNG-IUS in perimenopausal women might be more beneficial than in women belonging to other age groups. Moreover, the insertion of LNG-IUS during the perimenopausal period could confer endometrial protection during estrogen replacement therapy. In this review, we discuss the use of LNG-IUS in perimenopausal women.</p>","PeriodicalId":16410,"journal":{"name":"Journal of Menopausal Medicine","volume":"27 2","pages":"49-57"},"PeriodicalIF":0.0,"publicationDate":"2021-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ef/87/jmm-27-49.PMC8408317.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39371517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Effects of a Saffron Extract (affron®) on Menopausal Symptoms in Women during Perimenopause: A Randomised, Double-Blind, Placebo-Controlled Study.","authors":"Adrian L Lopresti,&nbsp;Stephen J Smith","doi":"10.6118/jmm.21002","DOIUrl":"https://doi.org/10.6118/jmm.21002","url":null,"abstract":"<p><strong>Objectives: </strong>There is preliminary evidence suggesting saffron may effectively treat menopausal symptoms. The aim of this study was to examine the tolerability and efficacy of a standardised saffron extract (affron®) on menopausal complaints in perimenopausal women.</p><p><strong>Methods: </strong>In this 12-week, parallel-group, double-blind, randomised controlled trial, 86 perimenopausal women experiencing menopausal complaints received either a placebo or 14 mg of a saffron extract (affron®), twice daily. Outcome measures included the Greene Climacteric Scale (GCS), Positive and Negative Affect Schedule (PANAS), and Short Form-36 Health Survey (SF-36).</p><p><strong>Results: </strong>Based on data collected from 82 participants, saffron was associated with greater improvements in mood and psychological symptoms compared to the placebo. Results from the GCS revealed a significantly greater reduction in the GCS psychological score (<i>P</i> = 0.032), characterised by a 33% reduction in anxiety and a 32% reduction in depression scores from baseline to week 12. There was also a significantly greater reduction in the PANAS negative affect score (<i>P</i> = 0.043) compared to the placebo. However, compared to the placebo, saffron was not associated with greater improvements in vasomotor symptoms, somatic symptoms, or other quality of life measures. Saffron intake was well tolerated with no reported major adverse events.</p><p><strong>Conclusions: </strong>The saffron extract, affron®, administered for 12 weeks at a dose of 14 mg twice daily was associated with greater improvements in psychological symptoms. Further studies in perimenopausal women presenting with varying severity of menopausal symptoms, using different doses of saffron will be useful to examine in future clinical trials.</p>","PeriodicalId":16410,"journal":{"name":"Journal of Menopausal Medicine","volume":"27 2","pages":"66-78"},"PeriodicalIF":0.0,"publicationDate":"2021-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/5e/af/jmm-27-66.PMC8408316.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39371519","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Associations between Polymorphisms in Phase II Enzymes and Circulating Sex-Steroid Hormones in White Postmenopausal Women.","authors":"Andrea Y Arikawa,&nbsp;Hamed Samavat,&nbsp;Mindy S Kurzer","doi":"10.6118/jmm.21005","DOIUrl":"https://doi.org/10.6118/jmm.21005","url":null,"abstract":"<p><strong>Objectives: </strong>The purpose of this cross-sectional study was to examine whether single nucleotide polymorphisms (SNPs) in enzymes that metabolize sex steroid hormones were associated with the blood levels of these hormones in postmenopausal women and if the use of menopausal hormone therapy (MHT) could modify this association.</p><p><strong>Methods: </strong>Baseline data were collected from 932 postmenopausal women enrolled in the Minnesota Green Tea Trial. Participants filled out a questionnaire about their demographics, lifestyle factors, and medical and reproductive history. Free, bioavailable, and total serum levels of reproductive hormones were measured through liquid chromatography/tandem mass spectrometry. For genotyping of <i>UGT1A1</i> (rs10928303), <i>UGT1A4</i> (rs10929301, rs11673726), <i>UGT1A6</i> (rs1105879, rs2070959, rs6759892), <i>UGT1A8</i> (rs10167119), <i>UGT2B7</i> (rs7439366), and <i>SULT1A1</i> (rs9282861, rs1968752), mass spectrometry based on multiplex methods and TaqMan assays were performed. Adjusted linear models were fit to assess the associations between SNPs and blood hormones using age, body mass index (BMI), and MHT as covariates.</p><p><strong>Results: </strong>The mean age was 59.8 years, and the mean BMI was 25.1 kg/m². Past or recent use of MHT was reported by 41.2% of the participants. SNPs in <i>SULT1A1</i> (rs1968752 and rs9282861) and <i>UGT1A4</i> (rs11673726) genes were significantly associated with estrone levels, whereas SNPs in <i>UGT1A6</i> (rs6759892) and <i>UGT1A8</i> (rs10167119) genes were significantly associated with bioavailable estradiol levels.</p><p><strong>Conclusions: </strong>There was no evidence that MHT use modified the association between SNPs and sex-steroid hormone levels; however, further studies are needed to establish the potential clinical significance of <i>UGT1A4</i> (rs11673726), <i>UGT1A6</i> (rs6759892), and <i>UGT1A8</i> (rs10167119) SNPs and the modulation of hormone levels in postmenopausal women.</p>","PeriodicalId":16410,"journal":{"name":"Journal of Menopausal Medicine","volume":"27 2","pages":"79-86"},"PeriodicalIF":0.0,"publicationDate":"2021-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/6f/e6/jmm-27-79.PMC8408318.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39371520","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of Evening Primrose Oil on Postmenopausal Psychological Symptoms: A Triple-Blind Randomized Clinical Trial.","authors":"Faranak Safdari, Bahareh Motaghi Dastenaei, Soleiman Kheiri, Zohreh Karimiankakolaki","doi":"10.6118/jmm.21010","DOIUrl":"10.6118/jmm.21010","url":null,"abstract":"<p><strong>Objectives: </strong>Psychological symptoms of menopause may impose a negative effect on the quality of life of menopausal women. Thus, the management of these symptoms can improve the quality of life and psychological health of such woman. The present study aimed to determine the effect of evening primrose on psychological symptoms in menopausal women.</p><p><strong>Methods: </strong>In this triple-blind randomized clinical trial, the effect of the evening primrose oil on postmenopausal psychological symptoms was investigated. The subjects were 100 menopausal women, referred to a healthcare center in Dastena city (Chaharmahal and Bakhtiari Province, Iran), who were randomly assigned to two groups. The intervention group used two 1 g pearls of evening primrose oil daily. The study instruments included a sub-scale of Menopause Rating Scale (MRS). Menopause data were analyzed using an independent <i>t</i>-test and Friedman test by the SPSS software. <i>P</i> values < 0.05 were considered statistically significant.</p><p><strong>Results: </strong>The two groups were balanced in demographic characteristics and psychological disorder severity before the intervention. The median (interquartile range) MRS score in the intervention group before the intervention and 2 and 4 weeks after the intervention were 11 (10-12), 6 (5-7), and 3 (2-4), respectively, and in the placebo, they were 11 (9-11), 10 (9-11), and 11 (10-12). A significant reduction was observed in the intervention group compared with the placebo group 2 and 4 weeks post-intervention.</p><p><strong>Conclusion: </strong>The use of evening primrose oil can decrease postmenopausal psychological symptoms.</p>","PeriodicalId":16410,"journal":{"name":"Journal of Menopausal Medicine","volume":"27 2","pages":"58-65"},"PeriodicalIF":0.0,"publicationDate":"2021-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/59/6b/jmm-27-58.PMC8408320.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39371518","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Minimal Invasive Myomectomy with Morcellation for Giant Myoma: A Challenge or a Questionable Approach?","authors":"Christos Iavazzo,&nbsp;Ioannis D Gkegkes","doi":"10.6118/jmm.21014","DOIUrl":"https://doi.org/10.6118/jmm.21014","url":null,"abstract":"<p><p>This study aimed to discuss the possible role of morcellation for a giant myoma in the minimal invasive approach. Current literature, including U.S. Food and Drug Administration guidelines, was reviewed. We found that safety of morcellation for a giant myoma is questionable. The risk and benefits of morcellation as well as alternative treatment options should be discussed with each individual patient.</p>","PeriodicalId":16410,"journal":{"name":"Journal of Menopausal Medicine","volume":"27 2","pages":"106-107"},"PeriodicalIF":0.0,"publicationDate":"2021-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/bf/39/jmm-27-106.PMC8408321.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39369436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Updates on Therapeutic Alternatives for Genitourinary Syndrome of Menopause: Hormonal and Non-Hormonal Managements.","authors":"Suhyun Shim,&nbsp;Kyung Min Park,&nbsp;Youn Jee Chung,&nbsp;Mee Ran Kim","doi":"10.6118/jmm.20034","DOIUrl":"https://doi.org/10.6118/jmm.20034","url":null,"abstract":"<p><p>Postmenopausal atrophic vaginitis, along with vasomotor symptoms and sleep disorders, is one of the most troublesome symptoms of menopause. However, many women do not manage this symptom properly due to insufficient knowledge of the symptoms or sexual embarrassment. With appropriate treatment, many postmenopausal women can experience relief from discomforts, including burning sensation or dryness of the vagina and dyspareunia. Topical lubricants and moisturizers, systemic and local estrogens, testosterones, intravaginal dehydroepiandrosterones (DHEAs), selective estrogen receptor modulators, and energy-based therapies are possible treatment modalities. Systemic and local estrogen therapies effectively treat genitourinary syndrome of menopause (GSM), but they are contraindicated in patients with breast cancer, for whom lubricants and moisturizers must be considered as the primary treatment. Intravaginal DHEA and ospemifene can be recommended for moderate to severe GSM; however, there is insufficient data on the use of intravaginal DHEA or ospemifene in patients with breast cancer, and further studies are needed. Energy-based devices such as vaginal laser therapy reportedly alleviate GSM symptoms; however, the U.S. Food and Drug Administration warning has recently been issued because of complications such as chronic pain and burning sensations of the vagina. To summarize, clinicians should provide appropriate individualized treatment options depending on women's past history, symptom severity, and chief complaints.</p>","PeriodicalId":16410,"journal":{"name":"Journal of Menopausal Medicine","volume":"27 1","pages":"1-7"},"PeriodicalIF":0.0,"publicationDate":"2021-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c0/8f/jmm-27-1.PMC8102810.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38945620","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Congenital Uterine Anomaly and Pelvic Organ Prolapse: A Rare Case of Pelvic Organ Prolapse in a Complete Bicornuate Uterus with Successful Pregnancy Outcomes Undiagnosed until the Time of Sacrocolpopexy.","authors":"Gina Nam,&nbsp;Sa Ra Lee","doi":"10.6118/jmm.21007","DOIUrl":"https://doi.org/10.6118/jmm.21007","url":null,"abstract":"<p><p>Müllerian development anomalies (MDAs) are most commonly diagnosed in the reproductive period. A bicornuate uterus is the result of a fusion defect of the Müllerian ducts, causing an abnormal fundal outline. Most of the cases are diagnosed early in life and present with obstetrical complications, such as recurrent pregnancy loss, preterm birth, intrauterine growth restriction, placental abruption, and cervical incompetence. Pelvic organ prolapse (POP) in women with MDAs has been reported; however, all reported cases were when MDAs are diagnosed before or simultaneously with the development of POP in premenopausal young women aged < 35. A 52-year-old menopausal woman, who successfully delivered vaginally at term, was presented with protruding mass through vaginal introitus. On POP-Q examination, the cervix was elongated and descended to 1 cm out of the hymen during bearing down; however, the uterine bodies were confined in the pelvic cavity, which is commonly encountered among POP patients with large uterus due to uterine fibroids or adenomyosis. She also diagnosed for complete bicornuate uterus and underwent robotic sacrocolpopexy for advanced stage POP. It is presumed to have been caused by the bicornuate uterus that prevented the total uterine prolapse with the effect of extending both uterine horns bilaterally inside the pelvic cavity and trapping the uterus within the pelvis. Herein, we report a rare case of complete bicornuate uterus with multiple successful vaginal deliveries at term without obstetric complications, which remained undiagnosed until she was managed for the POP in her postmenopausal period.</p>","PeriodicalId":16410,"journal":{"name":"Journal of Menopausal Medicine","volume":"27 1","pages":"32-36"},"PeriodicalIF":0.0,"publicationDate":"2021-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/dc/e3/jmm-27-32.PMC8102811.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38865399","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}